B2BINPAY
14.2.2024 09:22:28 CET | Business Wire | Press release
B2BinPay, the trusted blockchain-backed payment platform, has officially released its version 19 update to the public. This upgrade boasts many enhancements, including state-of-the-art instant swaps and expanded support for various blockchains. As always, B2BinPay remains dedicated to providing a seamless and secure platform for all cryptocurrency transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214263094/en/
B2BinPay v19 goes live with instant swaps and expanded blockchain support (Photo: Business Wire)
New Instant Swaps and Competitive VWAP-powered Rates
Swaps have become a preferred strategy for managing digital assets due to the direct exchange of cryptocurrencies between different addresses. This is a contrarian approach to conventional exchanges, which use the order books system for asset trading.
With B2BinPay, clients can easily access instant swaps without navigating through complicated order books and comparing prices across different venues. This is made possible with the Volume-Weighted Average Price (VWAP) tool, which automatically selects the best available price from multiple centralised platforms based on transaction volume.
In addition, the use of swaps by B2BinPay clients eliminates two blockchain commission costs, namely, the transaction to the centralised exchange and the transaction back to the B2BinPay wallet, which adds flexibility and cost-effectiveness in dealing with digital assets.
Instant swaps can be accessed through the dedicated Swaps Tab on the platform's front-end menu, along with separate wallets for each crypto asset.
Commission-Free Wallet Funding, Smooth Swapping Process
The latest release introduces a customised top-up process for swap wallets tailored to different user categories. Those with digital wallets can now take advantage of swift transactions for instant fund transfers, while owners of blockchain wallets benefit from on-chain transactions that offer both transparency and security through recorded data on the blockchain. It is crucial to note that topping up must be done in the wallet's designated currency.
In addition, users can enjoy a commission-free top-up process from their B2BinPay accounts. Note that blockchain wallets will still incur a minimal fee for on-chain transactions.
New Blockchain Network Integration: Avalanche and Polygon
B2BinPay's latest release has integrated support for two in-demand blockchains, Polygon and Avalanche. This integration brings an array of stablecoin transaction options to the platform, including popular choices like USDT, USDC, DAI, FRAX, TUSD, and EUROC on new networks.
Known for its scalability and minimal transaction fees, Polygon is a popular choice for a large number of crypto users. In comparison, Avalanche shines with its high throughput and rapid processing times, providing a powerful platform for speedy transfers.
Final Remarks
B2BinPay continues to push the boundaries of crypto processing with their latest version 19 release. This update offers clients even more flexibility, allowing them to access more blockchains and cryptocurrencies and make instant exchanges with swap wallets.
The team isn't stopping there – they are actively working on reducing fees to make their services even more cost-effective for all clients in future releases. This dedication to continuous improvement demonstrates B2BinPay's commitment to meeting the evolving needs of businesses and startups alike.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214263094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom